Tesamorelin

Growth Hormone SecretagogueResearch Use Only

Also known as: TH9507, Egrifta

Tesamorelin is a stabilized GHRH analog commonly referenced in research literature for its studied effect on visceral adipose tissue via stimulation of the growth-hormone/IGF-1 axis. It is one of the more clinically characterized GHRH analogs. This entry is educational and research-use-only and is not medical advice.

Typical range (research)

Commonly referenced in literature around 1–2 mg per day (research reference only)

Half-life

~25–40 minutes

Route

Subcutaneous (research)

Common use

Studied for effects on visceral fat and the growth-hormone axis in research contexts

Common vial sizes

5 mg · 10 mg · 20 mg

Storage

Lyophilized powder stored refrigerated or frozen away from light; reconstituted solution refrigerated (2–8 °C) and used within a few weeks

Stacking notes

Sometimes discussed alongside a GHRP for combined growth-hormone axis research; often studied on its own

Reported side effects

Injection-site reactionJoint aches reported anecdotallyFluid retention reported anecdotallyTransient glucose changes cited in studies

Regulatory note: Approved as a prescription drug (brand Egrifta) for a specific clinical indication in some jurisdictions; research-market products are sold for research purposes only

Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.